✦ LIBER ✦

Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States

✍ Scribed by Yuan, Yong; Trivedi, Digisha; Maclean, Ross; Rosenblatt, Lisa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS21 COST—EFFECTIVENESS OF RITUXIMAB VS

✍ LA Bynum; N Joshi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost effectiveness of adalimumab in the

✍ Bansback, N J 📂 Article 📅 2005 🏛 BMJ Publishing Group 🌐 English ⚖ 150 KB

PMS10 THE COST-EFFECTIVENESS OF ABATACEP

✍ Y Yuan; M Maier-Moldovan; R Maclean; GJ L'Italien 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PMS29 CANADIAN COST-EFFECTIVENESS ANALYS

✍ D Zou; O Desjardins; N Tsao; R Goeree 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Cost-effectiveness modeling of abatacept

✍ Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 183 KB

PMS34 AN EXPLORATORY EVALUATION OF THE C

✍ S Yunger; B Mistry 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB